PMC:7212949 / 5010-5337 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":108,"end":113},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma9576"}],"text":"\n• 54.6% unilateral, focal\n• 45.4% multifocal or bilateral\n• Peripheral zone predominant\nCT• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment\n• lll-defined peripheral GGO, usually subpleural • Leukopenia (2/3)\n• Lymphopenia (2/3)\n• CXR: Bilateral interstitial infiltrates • Abnormal CXR "}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T9","span":{"begin":108,"end":113},"obj":"Body_part"}],"attributes":[{"id":"A9","pred":"uberon_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"\n• 54.6% unilateral, focal\n• 45.4% multifocal or bilateral\n• Peripheral zone predominant\nCT• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment\n• lll-defined peripheral GGO, usually subpleural • Leukopenia (2/3)\n• Lymphopenia (2/3)\n• CXR: Bilateral interstitial infiltrates • Abnormal CXR "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T37","span":{"begin":233,"end":243},"obj":"Disease"},{"id":"T38","span":{"begin":252,"end":263},"obj":"Disease"}],"attributes":[{"id":"A37","pred":"mondo_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/MONDO_0003785"},{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0003783"}],"text":"\n• 54.6% unilateral, focal\n• 45.4% multifocal or bilateral\n• Peripheral zone predominant\nCT• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment\n• lll-defined peripheral GGO, usually subpleural • Leukopenia (2/3)\n• Lymphopenia (2/3)\n• CXR: Bilateral interstitial infiltrates • Abnormal CXR "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T21","span":{"begin":108,"end":113},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"}],"text":"\n• 54.6% unilateral, focal\n• 45.4% multifocal or bilateral\n• Peripheral zone predominant\nCT• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment\n• lll-defined peripheral GGO, usually subpleural • Leukopenia (2/3)\n• Lymphopenia (2/3)\n• CXR: Bilateral interstitial infiltrates • Abnormal CXR "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T27","span":{"begin":233,"end":243},"obj":"Phenotype"},{"id":"T28","span":{"begin":252,"end":263},"obj":"Phenotype"}],"attributes":[{"id":"A27","pred":"hp_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/HP_0001882"},{"id":"A28","pred":"hp_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/HP_0001888"}],"text":"\n• 54.6% unilateral, focal\n• 45.4% multifocal or bilateral\n• Peripheral zone predominant\nCT• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment\n• lll-defined peripheral GGO, usually subpleural • Leukopenia (2/3)\n• Lymphopenia (2/3)\n• CXR: Bilateral interstitial infiltrates • Abnormal CXR "}

{"project":"LitCovid-sentences","denotations":[{"id":"T48","span":{"begin":1,"end":26},"obj":"Sentence"},{"id":"T49","span":{"begin":27,"end":58},"obj":"Sentence"},{"id":"T50","span":{"begin":59,"end":88},"obj":"Sentence"},{"id":"T51","span":{"begin":89,"end":181},"obj":"Sentence"},{"id":"T52","span":{"begin":182,"end":249},"obj":"Sentence"},{"id":"T53","span":{"begin":250,"end":269},"obj":"Sentence"},{"id":"T54","span":{"begin":270,"end":276},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"\n• 54.6% unilateral, focal\n• 45.4% multifocal or bilateral\n• Peripheral zone predominant\nCT• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment\n• lll-defined peripheral GGO, usually subpleural • Leukopenia (2/3)\n• Lymphopenia (2/3)\n• CXR: Bilateral interstitial infiltrates • Abnormal CXR "}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1645","span":{"begin":61,"end":163},"obj":"GO:0007565"},{"id":"T67","span":{"begin":108,"end":113},"obj":"UBERON:0001443"},{"id":"T68","span":{"begin":287,"end":299},"obj":"UBERON:0005169"},{"id":"T473","span":{"begin":25,"end":35},"obj":"UBERON:0001004"},{"id":"T474","span":{"begin":112,"end":117},"obj":"UBERON:0000948"},{"id":"T475","span":{"begin":200,"end":205},"obj":"UBERON:0000178"},{"id":"T476","span":{"begin":220,"end":225},"obj":"UBERON:0000948"},{"id":"T477","span":{"begin":248,"end":253},"obj":"UBERON:0000948"},{"id":"T478","span":{"begin":306,"end":316},"obj":"UBERON:0002349"}],"text":"\n• 54.6% unilateral, focal\n• 45.4% multifocal or bilateral\n• Peripheral zone predominant\nCT• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment\n• lll-defined peripheral GGO, usually subpleural • Leukopenia (2/3)\n• Lymphopenia (2/3)\n• CXR: Bilateral interstitial infiltrates • Abnormal CXR "}